TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06629454

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adherence to digital incentive spirometer in the postop period after major chest surgery.
Description: Major chest surgery can lead to respiratory compromise and traditional breathing exercises are not supervised or monitored. The primary objective of this study is to evaluate the effect of a multifeatured digital IS and integrated phone app on patient adherence to incentive spirometry. Together the device and app will include the following functions: an auditory and haptic reminder cue, visual and auditory cues to guide exercise completion, exercise gamification, and data tracking and visualization features.
Study: NCT06630247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL495
Description: oral doses of XL495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL495
Description: oral doses of XL495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL495
Description: oral doses of XL495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADC cytotoxic agents
Description: intravenous infusion of anti-cancer combination agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADC cytotoxic agents
Description: intravenous infusion of anti-cancer combination agent
Study: NCT06778980

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The chin tuck posture
Description: A chin tuck is a posture correction technique where the individual gently tucks their chin towards their chest while keeping the rest of the body straight. This movement helps align the head and neck, reducing forward head posture and improving spinal alignment. After performing the unguided exercises, the patients will be taught the chin tuck position. From this point onward, they will be instructed to maintain the chin tuck position while performing the exercises using both external and internal focus strategies.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The chin tuck posture
Description: A chin tuck is a posture correction technique where the individual gently tucks their chin towards their chest while keeping the rest of the body straight. This movement helps align the head and neck, reducing forward head posture and improving spinal alignment. After performing the unguided exercises, the patients will be taught the chin tuck position. From this point onward, they will be instructed to maintain the chin tuck position while performing the exercises using both external and internal focus strategies.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The chin tuck posture
Description: A chin tuck is a posture correction technique where the individual gently tucks their chin towards their chest while keeping the rest of the body straight. This movement helps align the head and neck, reducing forward head posture and improving spinal alignment. After performing the unguided exercises, the patients will be taught the chin tuck position. From this point onward, they will be instructed to maintain the chin tuck position while performing the exercises using both external and internal focus strategies.
Study: NCT06632002

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DSF1
Description: 220 mL

Intervention type: OTHER
Group type: OTHER
Intervention: DSF2
Description: 220 mL
Study: NCT06778980

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The chin tuck posture
Description: A chin tuck is a posture correction technique where the individual gently tucks their chin towards their chest while keeping the rest of the body straight. This movement helps align the head and neck, reducing forward head posture and improving spinal alignment. After performing the unguided exercises, the patients will be taught the chin tuck position. From this point onward, they will be instructed to maintain the chin tuck position while performing the exercises using both external and internal focus strategies.
Study: NCT06779240

Intervention type: OTHER
Intervention: Quality of life questionnaires
Description: The clinical protocols at our institute involve the regular and continuous evaluation of the quality of life in patients undergoing treatment and monitoring for scoliosis and other vertebral deformities. To this end, the SRS-22 (Scoliosis Research Society) questionnaire and the ODI (Oswestry Disability Index) questionnaire are employed, along with other measures such as the COMI (Core Outcome Measure Index) and ISYQoL (Italian Spine Youth Quality of Life) and administrated to every patients
Study: NCT05647434

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sustained inflations
Description: Sustained inflation will be applied at a pressure of 30 cmH2O and will be held for a period of 30 secs. After each SI the standard ventilatory settings will be resumed with a PEEP setting of 8 cmH2O to prevent lung derecruitment. Lung recruitment will be stopped immediately if mean arterial pressure and/or heart rate change by at least 25% from baseline values.
Study: NCT06778681

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cheer
Description: During voluntary muscle contraction subjects will be cheered with verbal encouragement (push, push, push) and clapping.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cheer
Description: During voluntary muscle contraction subjects will be cheered with verbal encouragement (push, push, push) and clapping.
Study: NCT06778109

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hypnosis
Description: T0) basal evaluation of physiological data T1) evaluation of physiological data after recollecting a negative memory for 3 minutes T2) evaluation of physiological data after that a brief session of hypnosis (performed with positive memories) T3) evaluation of physiological data recolling, for the second time, the negative memory.
Study: NCT06778707

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: External Oblique Intercostal Block
Description: In group E, a needle will be used to pierce the skin, subcutaneous tissue then external oblique muscle to hydrodissect the fascial plane between external oblique muscle and intercostal muscles with 25 ml bupivacaine 0.25 % and 4 mg dexamethasone added to it.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subcostal Transversus Abdominis Plane Block
Description: In group T, a needle will be used to pierce the skin, subcutaneous tissue then rectus muscle and 25 ml of 0.25 % bupivacaine with 4 mg dexamethasone will be injected between rectus muscle and transversus abdominis muscle.
Study: NCT06779513

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiohraphy
Description: Transthoracal echocardiography for diastolic function assessment

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiohraphy
Description: Transthoracal echocardiography for diastolic function assessment
Study: NCT06779370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Silicate
Description: Root canal filling was removed with endodontic file. Sterile paper points were placed at working length to assess antibacterial and antifungal effects before the medicament was placed. Subsequently, the root canals were chemomechanically prepared, final irrigation activation was performed, and second samples were collected in the same manner. The calcium silicate-based root canal medicament was placed in the canals, and the teeth were sealed with temporary fillings. A form was provided to evaluate the patients' postoperative pain levels over one week. At the second appointment, the medicament was removed, and third samples were collected to assess antibacterial effects. The root canal treatments of the patients were completed. The antibacterial and antifungal effects of the medicaments were evaluated using PCR, and the patients' postoperative pain levels were recorded using follow-up forms.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium hydroxide
Description: Root canal filling was removed with endodontic file. Sterile paper points were placed at working length to assess antibacterial and antifungal effects before the medicament was placed. Subsequently, the root canals were chemomechanically prepared, final irrigation activation was performed, and second samples were collected in the same manner. The calcium hydroxide-based root canal medicament was placed in the canals, and the teeth were sealed with temporary fillings. A form was provided to evaluate the patients' postoperative pain levels over one week. At the second appointment, the medicament was removed, and third samples were collected to assess antibacterial effects. The root canal treatments of the patients were completed. The antibacterial and antifungal effects of the medicaments were evaluated using PCR, and the patients' postoperative pain levels were recorded using follow-up forms.
Study: NCT06779305

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally invasive surgical application of Calcanail®
Description: The procedure involves making small incisions to insert a specialized nail into the bone to realign and stabilize the fracture. This approach minimizes damage to surrounding tissues, reduces the risk of wound complications, and allows for quicker recovery compared to traditional open surgery. after surgery, the patient will benefit from an immobilisation with a plaster boot without support for 3 weeks, followed by immobilisation with a removable walking boot for 3 weeks with partial support depending on the patient's pain.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immobilisation by cast boot
Description: The patient will be immobilised in a plaster cast without support for 3 weeks, followed by immobilisation in a removable walking boot for 3 weeks with partial support depending on the pain.
Study: NCT04871412

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Activity Recommendations
Description: 150 minutes moderate intensity aerobic exercise per week plus the addition of a resistance exercise program on 2 of those days

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychological Recommendations
Description: Activities with the intention of actively improving the participant's mental and emotional health
Study: NCT06364813

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COMPANION eHealth Program
Description: COMPANION consists of online, self-paced educational modules with information on a range of topics such as providing medical care, applying for financial aid and home aid, working on the relationship with the care recipient, dealing with mental health issues, and learning life skills.
Study: NCT06632002

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care (SOC)
Description: Standard of care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care (SOC)
Description: Standard of care
Study: NCT06629779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06821497
Description: Oral continuous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Oral continuous
Study: NCT06352619

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conservative SBP Control
Description: No or minimal treatment; if there is a need to treat a patient with a very-high (\>180 mmHg) baseline SBP, then the SBP reduction is 5-10mmHg or a target is 175-180 mmHg

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate SBP Control
Description: If the patient has a very high (\>180 mmHg) or moderate high (160-180 mmHg) baseline SBP, SBP reduction is 10-20mmHg or a target of160±5 mmHg, which is higher; patients with low-high (150-160 mmHg) baseline SBP will not be treated

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive SBP Control
Description: SBP reduction by 30-50mmHg or a target of 140±5 mmHg, which is higher
Study: NCT06088758

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Normothermic machine perfusion (NMP) of steatotic liver
Description: Steatotic liver grafts that are selected will be run on NMP to assess quality of graft and determine whether it meets criteria for transplantation
Study: NCT06275477

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga-FAPI46
Description: Depending on the situation, it is planned that this evaluation will be transversal (performing \[68Ga\] Ga-FAPI PET/CT at baseline) or longitudinal (performing \[68Ga\] Ga-FAPI PET/CT at baseline and at 3/6 months for patients benefiting from an intensification of therapeutic management at inclusion).
Study: NCT06648135

Intervention type: PROCEDURE
Intervention: Immediate implants with bone grafts
Description: Immediate implants with bone grafts

Intervention type: PROCEDURE
Intervention: Immediate implant placed without bone grafts or any grafting substitutes in the labial gap
Description: Immediate implant placed without bone grafts or any grafting substitutes in the labial gap
Study: NCT05148988

Intervention type: DIAGNOSTIC_TEST
Intervention: EchoPIV
Description: All patients will undergo an echoPIV measurement 6 to 8 weeks before and 6 to 8 weeks after endovascular aneurysm repair. These measurements will take place at the Vascular Center of Rijnstate Hospital. A venous cannula will be inserted to enable contrast administration. Ultrasound data will be collected at the caudal renal artery, infrarenal neck, aneurysm sac and both iliac arteries.

Intervention type: DIAGNOSTIC_TEST
Intervention: 4D flow MRI
Description: A 4D phase-contrast magnetic resonance imaging (4D flow MRI) scan of the abdominal aorta will be obtained 6 to 8 weeks before and 6 to 8 weeks after endovascular aneurysm repair.
Study: NCT05321992

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: eCHEC program
Description: The eCHEC program is the enhanced Community-based Health Education and Communication (CHEC) model to prevent O. viverrini in an effort to decrease cholangiocarcinoma (CCA) in Khon Kaen, Thailand
Study: NCT06268015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botensilimab
Description: 75 mg IV every 6 weeks for up to 4 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balstilimab
Description: 240 mg IV every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/m2 IV every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 400 mg/m2 IV every 2 weeks
Study: NCT06629779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Oral continuous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzalutamide
Description: Oral continuous
Study: NCT06690658

Intervention type: DEVICE
Group type: OTHER
Intervention: incorporating robotic system for upper body physical training of people with lower limb orthopedic condition
Description: A training session begins with the robot introducing itself, and the participant sits in front of the robot. The robot will demonstrate upper body exercises and will provide verbal instructions and feedback (e.g, number of successful repetitions, motivational). At the beginning of the session, the participant will be asked to follow the robot's demonstration and simultaneously perform the exercise. At the end of each exercise, the robot will provide feedback. If the participant successfully performed ten repetitions of the required exercise in the demonstration time allocated, positive feedback will be provided. Resistance (strengthening) exercises for the upper body include lifting weights, working with resistance bands in different directions involving the upper extremity and trunk. Flexibility exercises include upper extremity and trunk stretching.
Study: NCT06686849

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-touch: texting
Description: Text message: The patients' primary caregiver will be sent up to three text messages spaced one week apart, starting at one week post no-show. The message will identify the child by the first name and give information about the missed visit (date, time, clinic location) and how to reschedule (by clinic-specific phone number, and/or directing the patient to myatriumhealth.org). If a patient has a newly scheduled well-child visit on file prior to all three text messages being sent, messages will be stopped.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-touch: Community health worker outreach
Description: Community health worker (CHW) outreach: Within approximately one week of patient enrollment and randomization to the high-touch intervention arm, the community health worker will call the primary phone number in the patient's record. Up to three phone call attempts will be made and logged for this number, then a fourth and final attempt will be made to reach the secondary contact phone number in the patient's health record. If the caregiver is successfully reached, the CHW intervention will be limited to one phone call in which the CHW will assess reason(s) why the patient missed the appointment, will screen for social and other needs, and will assist in rescheduling the missed appointment and addressing potential barriers to attendance.
Study: NCT06630611

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: NMA-LD regimen
Description: The use of the NMA-LD regimen (cyclophosphamide and fludarabine) prior to cell administration is expected to lead to myelosuppression in all patients.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NMA-LD regimen
Description: The use of the NMA-LD regimen (cyclophosphamide and fludarabine) prior to cell administration is expected to lead to myelosuppression in all patients.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tumor infiltrating lymphocytes adoptive cell therapy (TIL-ACT) infusion
Description: On Day 0 (at least 24h after the last dose of fludarabine) patients will be hospitalized in a dedicated unit. Autologous TIL infusion will be administered intravenously.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor infiltrating lymphocytes adoptive cell therapy (TIL-ACT) infusion
Description: On Day 0 (at least 24h after the last dose of fludarabine) patients will be hospitalized in a dedicated unit. Autologous TIL infusion will be administered intravenously.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: High dose IL-2
Description: Only for patients in Arm A.~IL-2 begins between 3 and 24 hours after the completion of the TIL infusion and is given as a bolus administration every eight hours (minimum interval) to 24 hours (maximum interval) with a maximum of six doses from the beginning of each administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-2 analog
Description: Only for patients in Arm B~ANV419 will be administered between 3 and 24 hours after the completion of the TIL infusion with a slow IV infusion over 15-30 minutes + 5 minutes once, at 243µg/kg.
Study: NCT04946838

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: DS5 electrical stimulator
Description: TENS

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DS5 electrical stimulator
Description: TENS
Study: NCT06268015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: 400 mg/m2 IV bolus + 2,400 mg/m2 IV (over 46 hours) every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 5 mg/kg IV every 2 weeks
Study: NCT05807139

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT06690138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Divarasib
Description: Divarasib will be administered as a single oral dose as specified for the respective period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Divarasib
Description: Divarasib will be administered as a single oral dose as specified for the respective period.
Study: NCT06056336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab 200 mg q21d up to 1 year. Nad-paclitaxel 260 mg/m2, IV., every 3 weeks, 2-3 cycles. Carboplatin area under the curve = 5, IV., every 3 weeks, 2 cycles.
Study: NCT04659174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xanomeline and Trospium Chloride Capsules
Description: Oral xanomeline 50 mg/trospium chloride 20 mg BID on days 1-2 followed by xanomeline 100 mg/trospium chloride 20 mg BID on days 3-7. The dosage is increased to xanomeline 125 mg/trospium chloride 30 mg BID on days 8-364 unless the subject is experiencing adverse events from the xanomeline 100 mg/ trospium chloride 20 mg dose. Subjects who were increased to xanomeline 125 mg/trospium chloride 30 mg will have the option to return to xanomeline 100 mg/ trospium chloride 20 mg depending on clinical response and tolerability. Re-escalation to 125/30 BID or re-titration in cases in which the subject has been off KarXT for a longer period of time (at least a week) is allowed and will require a discussion between the principal investigator and the medical monitor.
Study: NCT05071872

Intervention type: DEVICE
Intervention: Atherectomy/Thrombectomy
Description: Percutaneous transluminal removal of thrombotic occlusion in arteriovenous graft

Intervention type: DEVICE
Intervention: Atherectomy/Thrombectomy
Description: Percutaneous transluminal removal of thrombotic occlusion in arteriovenous graft
Study: NCT05935891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD-dominant
Description: product contains 2210 mg CBD and less than 0.3% THC per 1.5 ounce jar. Patients will be provided a 2-week supply of creams (3 jars for each 14 day interval) by Vireo Health, according to the randomization arm. Patient will be instructed to apply the topical products using the 1.25cc spoon provided (there are approximately 35 scoops per 1.5oz jar). The patient will apply one scoop of cream to the back of each hand and then rub into the entire hand, wrist, and all fingers. After the 14 day assessment, patients will be transitioned to a two-week open label extension that allows them to choose their preference of either Red XS or Violet cream at no cost.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC dominant
Description: contains 375mg THC and less than 20mg CBD per 1.5 ounce jar. Patients will be provided a 2-week supply of creams (3 jars for each 14 day interval) by Vireo Health, according to the randomization arm. Patient will be instructed to apply the topical products using the 1.25cc spoon provided (there are approximately 35 scoops per 1.5oz jar). The patient will apply one scoop of cream to the back of each hand and then rub into the entire hand, wrist, and all fingers. After the 14 day assessment, patients will be transitioned to a two-week open label extension that allows them to choose their preference of either Red XS or Violet cream at no cost.